Investors and Media
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:
- Human Therapeutics
- High-value Research Tools
- Transgenic Animals
- Cell-line Engineering for Protein Manufacturing
- Plant Agriculture
View all »
Recent Releases
Jan 9, 2012
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials
Jan 5, 2012
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference




